UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 5, 2007
BRADLEY PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of
incorporation) | | 0-31680
(Commission File Number) | | 22-2581418
(IRS Employer
Identification No.) |
383 Route 46 West, Fairfield, New Jersey
(Address of principal executive offices) | | | 07004
(Zip Code) |
Registrant’s telephone number, including area code:(973) 882-1505
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |_| | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |_| | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |_| | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |_| | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry Into A Material Definitive Agreement
On October 5, 2007, Bradley Pharmaceuticals, Inc. (the “Company”) entered into an Amendment, Extension and Novation (the “Amendment”) to its Core Distribution Agreement (the “Distribution Agreement”) with McKesson Corporation (“McKesson”). Under the Distribution Agreement, as amended, the Company pays McKesson, under certain circumstances, a fee in exchange for certain product distribution, logistics and inventory management and administrative services. The Company intends to file the Amendment as an exhibit to the Company’s Form 10-Q for the quarter ended September 30, 2007. The Company expects to request confidential treatment for portions of the Amendment in accordance with the procedures of the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | BRADLEY PHARMACEUTICALS, INC. |
| | | |
| | By: | /s/ R. Brent Lenczycki CPA
|
| | | R. Brent Lenczycki, CPA
Chief Financial Officer and
Vice President |
Dated: October 10, 2007
